Keep up to date by subscribing to our newsletter Perspectives.
26 April is World IP Day! This year's theme is 'Women and IP: Accelerating innovation and creativity', which provides an opportunity to talk about why it is important for women to be part of climate change innovation solutions, and to highlight a few of the women leading the way.
As a tech start-up specialist, Silicon Valley Bank (SVB) held pledges on numerous patent rights. Rose-Marie Ehanno explains how patent pledges work and what the collapse of SVB means for affected patent holders.
A recent decision by the European Patent Office on neural network patentability has interesting implications for artificial intelligence and other computer-derived innovations, says Martin Kohrs.
On 17 February, Germany ratified the Unified Patent Court Agreement. This means that the Unitary Patent and Unified Patent Court system will enter into force as planned on 1 June 2023, with the Sunrise period beginning on 1 March 2023.
With the Unitary Patent and Unified Patent Court system on the horizon, the first question for European patent rights holders is whether to opt-out from the jurisdiction of the UPC before the system comes into force.
A November 2022 decision by the Boards of Appeal of the European Patent Office addresses several issues relating to the sufficiency of disclosure in patent descriptions.
A thorough review of your trademark portfolio now will put both your IP rights and your business in a strong position for the year to come. Assess your registrations for strength, accuracy and cost with the help of our three-step process.
With the imminent entry into force of the Unified Patent Court Agreement, the countdown has begun to opt-out of the jurisdiction of the new European court. Marie-Noëlle de la Fouchardière explains what can be opted out, by whom and how to simplify the management of opt-out declarations.
Whether you choose to file a patent application or keep a new invention secret, it’s crucial to take steps to minimise the risks of disclosure. Rose-Marie Ehanno explains how to keep patentable inventions confidential.
Must a compound be shown to be suitable for each disease for first medical use claims to be sufficiently disclosed in applications for European patents, asks Matthieu Boulard.
In a recent webinar on best practices for European patents, Novagraaf’s Dr Kate McNamara joined experts from Questel to discuss the new European patenting landscape. Here, we summarise some of the key points discussed.
Patents to protect innovation are applied for and owned only by their ‘human’ inventor, so what happens if a product is produced entirely and autonomously by a highly advanced computer? This question has been at the heart of a number of proceedings before patent offices around the world, including the EPO, as Volha Parfenchyk explains.